anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The disruption of endothelial barrier integrity leading to increased vascular permeability contributes to many pathological processes. In a first cohort of 11 patients having cardiac arrest with vascular leakage, the inventors identified that AREG is 56-fold more expressed than control. During a second prospective clinical study, they confirmed a strong association between the plasma level of AREG and the fluid balance in 77 independent patients hospitalized for a cardiogenic shock. The inventors finally showed a crucial role for this protein in Areg-/- mice, with i) no KO-mice achieving a return of spontaneous circulation (ROSC) vs. 40% in WT mice (n=6 per group, p<0.05) and ii) a beneficial effect of 10 µg recombinant AREG i.v. injection at the time of resuscitation, with 80% injected mice that achieve a ROSC vs 40% in controls (n=6, p<0.05). Finally, using markers of vascular extravasation, they demonstrated that AREG administration was decreasing the level of vascular leakage. The results thus indicate that administering AREG in a patient suffering from vascular permeability would be beneficial. Thus, the present invention relates to the use of amphiregulin (AREG) in methods of treating vascular permeability.
The present invention relates to the administration of a prenylated isoflavone and its effects on subjects with multidrug-resistant cancer, in particular a multidrug-resistant cancer with enhanced expression or functional activity of ABC transporter proteins such as P-glycoprotein, i.e. a specific subgroup of subjects with cancer. It has been found that the prenylated isoflavone is suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in said cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit comprising a prenylated isoflavone and a chemotherapeutic compound is provided. WORK, Fig 1'A~ (.-.ily 3 Fi .
PROBLEM TO BE SOLVED: To prepare the subject therapeutic agent useful for treating memory (retention) disorder and acquiring the memory in Alzheimer type dementia by including propentofylline as an active ingredient therein. SOLUTION: This therapeutic agent for memory disorder comprises propentofylline of the formula which is 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7- propyl-1H-purine-2,6-dione as an active ingredient. Since the toxicity of the compound of the formula is low, continuous administration of the therapeutic agent can be carried out and the daily dose is preferably 100-1,500mg, based on the amount of the active ingredient and intravenously, intramuscularly, perorally and intrarectally administered. In the case of the intravenous administration, intravenous drip can be performed in addition to the intravenous injection.  A powdery pharmaceutical preparation can be obtained as the pharmaceutical preparation for parenteral injection by adding, e.g. a water-soluble excipient to the compound of the formula, dissolving the resultant mixture in water, distributing the resultant solution into each ampul, etc., then freeze-drying the distributed solution and hermetically sealing the ampul. A tablet, a capsule, a powder, etc., can be prepared as a peroral pharmaceutical preparation and further an enteric pharmaceutical preparation.
1. Pantoprazole magnesium dihydrate. 2. A medicament comprising pantoprazole magnesium dehydrate together with customary auxiliaries. 3. Pantoprazole magnesium dehydrate for use in the treatment of disorders of the stomach or intestine. 4. A combination medicament comprising pantoprazole magnesium dehydrate and pantoprazole sodium sesquihydrate. 5. A combination medicament comprising pantoprazole magnesium dehydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 10% pantoprazole magnesium dihydrate and 90% pantoprazole sodium sesquihydrate to 90% pantoprazole magnesium dihydrate and 10% pantoprazole sodium sesquihydrate. 6. A combination medicament comprising pantoprazole magnesium dehydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 25% pantoprazole magnesium dehydrate and 75% pantoprazole sodium sesquihydrate to 75% pantoprazole magnesium dehydrate and 25% pantoprazole sodium sesquihydrate. 7. A combination medicament comprising pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 40% pantoprazole magnesium dehydrate and 60% pantoprazole sodium sesquihydrate to 60% pantoprazole magnesium dihydrate and 40% pantoprazole sodium sesquihydrate.
A dry preparation having a foam-like and, respectively, fleece-like structure obtained by freeze-drying consists, apart from thrombin in at least catalytically active amounts, substantially of approx. 10 to 95% by weight of fibrin and approx. 5 to 90% by weight of fibrinogen. For the preparation thereof, fibrin is produced in situ in an aqueous solution containing fibrinogen and thrombin and the resultant reaction mixture is deep-frozen and lyophilized. As further constituents of the dry preparation active substances such as e.g. antibiotics, natural bone material and/or a synthetic, bone-forming substitute, glycoproteins, coagulation-conducive substances and the like and/or fibrinolysis inhibitors come into consideration. The dry preparation is provided mainly for use as a wound toilet material, as a filling material for bone cavities and/or as a supporting material for further active substances.
Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic medication for the treatment of various autoimmune conditions. A rare side effect of HCQ is thrombotic thrombocytopenic purpura (TTP). We present two cases of patients who developed purpura that did not meet TTP criteria following treatment with HCQ. While the etiology of HCQ-associated TTP is poorly understood, we propose a spectrum of manifestations related to HCQ, ranging from benign purpura to TTP. As multiple factors contribute to the disease, we believe that HCQ may act as a "second hit" in patients with genetic susceptibility, which also influences the variability in the severity of disease manifestations. J Drugs Dermatol. 2024;23(5):e124.     doi:10.36849/JDD.7781e.
AIMS: Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) using very high-power short-duration (vHPSD) radiofrequency (RF) ablation proved to be safe and effective. However, vHPSD applications result in shallower lesions that might not be always transmural. Multidetector computed tomography-derived left atrial wall thickness (LAWT) maps could enable a thickness-guided switching from vHPSD to the standard-power ablation mode. The aim of this randomized trial was to compare the safety, the efficacy, and the efficiency of a LAWT-guided vHPSD PVI approach with those of the CLOSE protocol for PAF ablation (NCT04298177).
METHODS AND RESULTS: Consecutive patients referred for first-time PAF ablation were randomized on a 1:1 basis. In the QDOT-by-LAWT arm, for LAWT ≤2.5 mm, vHPSD ablation was performed; for points with LAWT > 2.5 mm, standard-power RF ablation titrating ablation index (AI) according to the local LAWT was performed. In the CLOSE arm, LAWT information was not available to the operator; ablation was performed according to the CLOSE study settings: AI ≥400 at the posterior wall and ≥550 at the anterior wall. A total of 162 patients were included. In the QDOT-by-LAWT group, a significant reduction in procedure time (40 vs. 70 min; P < 0.001) and RF time (6.6 vs. 25.7 min; P < 0.001) was observed. No difference was observed between the groups regarding complication rate (P = 0.99) and first-pass isolation (P = 0.99). At 12-month follow-up, no significant differences occurred in atrial arrhythmia-free survival between groups (P = 0.88).
CONCLUSION: LAWT-guided PVI combining vHPSD and standard-power ablation is not inferior to the CLOSE protocol in terms of 1-year atrial arrhythmia-free survival and demonstrated a reduction in procedural and RF times.
Atherosclerosis is the most common cause of heart disease and stroke. Plaque thickness ≥4 mm in the ascending aorta or aortic arch is strongly correlated with cerebral embolic events and ischemic stroke. However, despite imaging workup, the cause of embolic stroke remains unidentified in many patients. Transesophageal echocardiography (TEE) is the preferred echocardiographic method for the evaluation of cardiac source of emboli. 2D TEE imaging evaluates aortic root and aortic arch in a single plane or two planes with biplane imaging. However, 2D TEE often fails to detect mobile or complex components in the ascending aorta and aortic arch plaques. The routine availability of 3D TEE in current ultrasound systems may significantly improve the assessment of aortic plaques as a potential embolic source. In this case series, we present four consecutive patients with stroke who underwent TEE by a single cardiologist for possible cardioembolic source. Some of these patients may have been labelled as "cryptogenic stroke" or "embolic stroke of undetermined source" (ESUS) due to the presence of insignificant or nonmobile ascending aortic or aortic arch plaques on 2D TEE imaging. In our four consecutive patients with ESUS who underwent TEE by a single operator, 3D TEE showed complex aortic arch plaques with ulceration with mobile components and established these plaques as the likely source of embolic stroke.
They will receive motivation and behavioral support through a study specific website which will be accessed after randomization. The research team will give participants further information on the use of this website. One of the features of the website will allow participants to collect and self-monitor their dietary intakes using 24h dietary recalls. Participants will be instructed to fill in as many recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. Other features of the website include specific indications to eliminate red and processed meat in the context of a healthy Mediterranean dietary pattern, considering the key elements proposed in the dietary guidelines to improve cardiovascular health. The website will also provide them general information about the Mediterranean diet, as well as recipes, tips, and alternatives to replace meat when cooking at home or eating out. The rest of the clinical care will be as usual.
Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the "Vocalization" domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital.
Hypertension is the leading risk factor of heart failure with preserved heart failure. The overall control rate is about 16% in China. Given the large amounts of hypertensive patients at pre-heart failure (stage B), it's critical to explore the effect of additional cardioprotective medication in addition to well-controlled blood pressure. Sodium-glucose cotransporter-2 inhibitors (engagliflozin) have been shown to improve cardiac function or prognosis in patients with diabetes or heart failure. However, whether it has a cardioprotective effect on hypertensive patients with pre-heart failure and without diabetes remains unknown. We will conduct a multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes. We will enroll 120 eligible patients randomized to receive a placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. The secondary endpoints include echocardiography or magnetic resonance imaging to measure structural and functional parameters, blood pressure, glucose, and blood biomarkers of inflammation and fibrosis. We sought to comprehensively evaluate the effect of empagliflozin on the structure and function and explore the underlying mechanisms to provide insights and evidence for the prevention of heart failure in hypertensive patients.
Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
BACKGROUND: The glenoid track concept has enabled the categorization of Hill-Sachs lesions (HSLs) into on-track lesions and off-track lesions. Furthermore, among the on-track lesions, further categorization has been established based on the distance from the medial edge of the Hill-Sachs lesion to the medial edge of the glenoid track, into peripheral-track lesions and central-track lesions. Recent studies on peripheral-track lesions and central-track lesions within the glenoid track have shown inconsistencies in failure rates, which deserves further investigation.
METHODS: A retrospective cohort comparison of patients who underwent arthroscopic Bankart repair between 2015 and 2020 was performed. 102 patients with peripheral-track HSLs were included. The patients were divided into 2 groups based on the results of the postoperative apprehension test: the apprehension positive group (n = 30), and the apprehension negative group (n = 72). Using preoperative computed tomography (CT) and an image reconstruction program, 3-dimensional (3D) images were segmented to calculate the length, width, depth, and distance of the HSLs. A multivariate logistic regression was used to determine the risk factors of recurrence, for which odds ratio (OR) and 95% confidence interval (CI) were provided.
RESULTS: A multivariate logistic regression analysis revealed that the length of the peripheral-track HSLs was a significant independent predictor of failure in this study. (OR 1.380; 95% CI 1.170-1.627; P < .001). The receiver operating characteristics curve (ROC) demonstrated a predictive power (area under the curve = 0.841) and a threshold value of 14.2 mm.
CONCLUSION: Length was the only risk factor for the recurrent instability of peripheral-track HSLs after ABR. In the context of surgical decision-making, utilizing the glenoid track concept, medical practitioners may need to evaluate instability by considering the length as a continuous factor, while differentiating between peripheral-track and central-track classifications.
Patients will perform a session (stimulation) of HD-TDCS of twenty minutes with intensity of 3 milliamps in the left temporal cortex. Before and after each session, patients will perform the six-minute walk test. Heart rate variability (HRV) will be evaluated throughout the protocol through Holter (3-channel). At the end, the perception of exertion and the level of dyspnea of the patient, distance covered and blood pressure will be evaluated.
The invention discloses a swine transmissible gastroenteritis S/N protein fusion gene, recombinant lactococcus lactis and application. The invention provides an antigen fusion gene obtained by connecting A and D antigen loci in swine transmissible gastroenteritis virus (TGEV) S protein and an N321 antigen locus in N protein and a streptococcus pyogenes cell wall anchoring sequence, and a nucleotide sequence of the antigen fusion gene is shown as SEQ ID No. 1. The invention further provides an expression vector containing the antigen fusion gene and the recombinant lactococcus lactis strain containing the recombinant expression vector. The recombinant lactococcus lactis strain is induced by using nisin, the fusion gene can be expressed on the surface of the bacterial cell wall. Immunoblotting experiments indicate that the expressed recombinant protein can react with TGEV immune serum and has the same antigenicity with TGEV natural antigens, and the recombinant protein can be prepared into safe and effective mucous immune live vaccines for preventing and treating swine transmissible gastroenteritis.
Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, or sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of propafenone hydrochloride with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided [see Warnings and Precautions (5.4) and Dosage and Administration (2)].

Amiodarone: Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended.

Cimetidine: Concomitant administration of propafenone immediate-release tablets and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone.  


Fluoxetine: Concomitant administration of propafenone and fluoxetine in extensive metabolizers increased the S-propafenone Cmax and AUC by 39% and 50%, respectively, and the R propafenone Cmax and AUC by 71% and 50%, respectively.

Quinidine: Small doses of quinidine completely inhibit the CYP2D6 hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers [see Clinical Pharmacology (12.3)]. Concomitant administration of quinidine (50 mg three times daily) with 150 mg immediate release propafenone three times daily decreased the clearance of propafenone by 60% in extensive metabolizers, making them slow metabolizers. Steady-state plasma concentrations more than doubled for propafenone and decreased 50% for 5-OH-propafenone. A 100 mg dose of quinidine tripled steady-state concentrations of propafenone. Avoid concomitant use of propafenone and quinidine.

Rifampin: Concomitant administration of rifampin and propafenone in extensive metabolizers decreased the plasma concentrations of propafenone by 67% with a corresponding decrease of 5-OH-propafenone by 65%. The concentrations of norpropafenone increased by 30%. In slow metabolizers, there was a 50% decrease in propafenone plasma concentrations and an increase in the AUC and Cmax of norpropafenone by 74% and 20%, respectively. Urinary excretion of propafenone and its metabolites decreased significantly. Similar results were noted in elderly patients: Both the AUC and Cmax propafenone decreased by 84%, with a corresponding decrease in AUC and Cmax of 5-OH-propafenone by 69% and 57%, respectively.
Participants underwent \~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
Isolated optic nerve (ON) relapse is a rare occurrence in lymphoblastic leukemia (LBL). A 10-year-old boy with T-LBL presented 8 months after diagnosis with blurred vision and thickening of right ON on magnetic resonance imaging consistent with relapse. Cerebrospinal fluid and bone marrow were negative for leukemia. He received reinduction chemotherapy (including nelarabine and craniospinal radiation) followed by a myeloablative matched sibling donor bone marrow transplant. He remains in remission 2 years post-transplant with normal vision. We also review the literature for reports of isolated ON relapse in patients with LBL. Our patient's clinical course demonstrates that disease control can be achieved with early detection of ON relapse before disease progression.
The striatum integrates dopaminergic and glutamatergic inputs to select preferred versus alternative actions. However, the precise mechanisms underlying this process remain unclear. One way to study action selection is to understand how it breaks down in pathological states. Here, we explored the cellular and synaptic mechanisms of levodopa-induced dyskinesia (LID), a complication of Parkinson's disease therapy characterized by involuntary movements. We used an activity-dependent tool (FosTRAP) in conjunction with a mouse model of LID to investigate functionally distinct subsets of striatal direct pathway medium spiny neurons (dMSNs). In vivo, levodopa differentially activates dyskinesia-associated (TRAPed) dMSNs compared to other dMSNs. We found this differential activation of TRAPed dMSNs is likely to be driven by higher dopamine receptor expression, dopamine-dependent excitability, and excitatory input from the motor cortex and thalamus. Together, these findings suggest how the intrinsic and synaptic properties of heterogeneous dMSN subpopulations integrate to support action selection.
Whilst western diet and sedentary lifestyles heavily contribute to the global obesity epidemic, it is likely that chemical exposure may also contribute. A substantial body of literature implicates a variety of suspected environmental chemicals in metabolic disruption and obesogenic mechanisms. Chemically induced obesogenic metabolic disruption is not yet considered in regulatory testing paradigms or regulations, but this is an internationally recognised human health regulatory development need. An early step in the development of relevant regulatory test methods is to derive appropriate minimum chemical selection lists for the target endpoint and its key mechanisms, such that the test method can be suitably optimised and validated. Independently collated and reviewed reference and proficiency chemicals relevant for the regulatory chemical universe that they are intended to serve, assist regulatory test method development and validation, particularly in relation to the OECD Test Guidelines Programme. To address obesogenic mechanisms and modes of action for chemical hazard assessment, key initiating mechanisms include molecular-level Peroxisome Proliferator-Activated Receptor (PPAR) α and γ agonism and the tissue/organ-level key event of perturbation of the adipogenesis process that may lead to excess white adipose tissue. Here we present a critical literature review, analysis and evaluation of chemicals suitable for the development, optimisation and validation of human PPARα and PPARγ agonism and human white adipose tissue adipogenesis test methods. The chemical lists have been derived with consideration of essential criteria needed for understanding the strengths and limitations of the test methods. With a weight of evidence approach, this has been combined with practical and applied aspects required for the integration and combination of relevant candidate test methods into test batteries, as part of an Integrated Approach to Testing and Assessment for metabolic disruption. The proposed proficiency and reference chemical list includes a long list of negatives and positives (20 chemicals for PPARα, 21 for PPARγ, and 11 for adipogenesis) from which a (pre-)validation proficiency chemicals list has been derived.